SLC5A2 and prostate cancer: As glucose is a major substrate required for cancer cell survival and growth, Scafoglio and colleagues hypothesized that the metabolism-shifting effect of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) might be protective against malignancy as well.169 In this seminal investigation, functional expression of SGLT2 on human pancreatic and prostate cancers was demonstrated.